Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
11.71
+0.31 (2.72%)
Aug 25, 2026, 4:00 PM EDT - Market closed

Fennec Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Fennec Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $17.67. The average 1-year stock price forecast is 50.90% higher than the current stock price, while the lowest is $16 (+36.64%) and the highest is $20 (+70.79%).

Price Target: $17.67 (+50.90%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$16$17.67$18$20
Change+36.64%+50.90%+53.71%+70.79%

Analyst Ratings

The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Aug '26
Strong Buy555544
Buy111222
Hold000000
Sell000000
Strong Sell000000
Total666766

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Buy
Reiterates
$15$20
BuyReiterates$15$20+70.79%Aug 13, 2026
Unknown Analyst
Wedbush
No rating
Wedbush
Buy
Maintains
$13$16
BuyMaintains$13$16+36.64%Aug 12, 2026
Craig-Hallum
Craig-Hallum
Buy
Reiterates
$16$18
BuyReiterates$16$18+53.71%Aug 12, 2026
Unknown Analyst
B. Riley Securities
No rating
B. Riley Securities
Buy
Initiates
$16$18
BuyInitiates$16$18+53.71%Aug 12, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$13$16
BuyReiterates$13$16+36.64%May 22, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
72.90M
from 44.64M
Increased by 63.30%
Revenue Next Year
103.15M
from 72.90M
Increased by 41.50%
EPS This Year
0.33
from -0.28
EPS Next Year
0.95
from 0.33
Increased by 185.03%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-1.54M21.25M47.54M44.64M72.90M
Revenue Growth
--1,284.50%123.69%-6.09%63.30%
Gross Profit
-1.45M19.99M44.35M40.88M69.86M
Gross Margin
-94.40%94.08%93.30%91.57%95.83%
Operating Income
-17.22M-22.59M-12.77M2.57M-6.28M10.45M
Net Income
-17.35M-23.71M-16.05M-436.00K-9.74M11.25M
EPS
-----0.280.33
Forward PE
6.326.3290.8537.3615.8835.06
Free Cash Flow
-7.73M-9.17M-12.35M-289.75K-7.33M11.40M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High74.0M
Avg72.9M
Low71.6M

Revenue Growth

Revenue Growth202620272028
High
65.8%
Avg
63.3%
Low
60.4%

EPS Forecast

EPS202620272028
High0.52
Avg0.33
Low0.20

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-